Loading
Stage Iv Lung Cancer AJCC V8 / Computed Tomography / Biopsy Procedure · Phase 2 Trial
ClinicalTrials.gov · August 12, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2 trial registry record comparing osimertinib with and without bevacizumab in EGFR-positive NSCLC with brain metastases. The study enrolled only 5 participants and has not published results. No efficacy or safety data are available from this registry entry.
Phase 2, Interventional, Randomized, Parallel, Open label, Treatment purpose. Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8; age from 18 Years. Intervention: Arm I (osimertinib, bevacizumab); Arm II (osimertinib). Compared with: Osimertinib with bevacizumab versus osimertinib alone. n = 5. 18 sites: United States.
This is a Phase 2 trial registry record comparing osimertinib with and without bevacizumab in EGFR-positive NSCLC with brain metastases. The study enrolled only 5 participants and has not published results. No efficacy or safety data are available from this registry entry.
This is a registry record with no results posted; no efficacy, safety, or outcome data are available.
The source did not state who this applies to in practice.
This is a Phase 2 trial registry record with only 5 enrolled participants and no results posted; it represents early-phase work that requires confirmation.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT02971501). This is a study registration, not published results. Lead sponsor: National Cancer Institute (NCI). Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 5 participants (ACTUAL). Conditions: Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8. Interventions: BIOLOGICAL: Bevacizumab; PROCEDURE: Biopsy Procedure; PROCEDURE: Biospecimen Collection; PROCEDURE: Computed Tomography; PROCEDURE: Magnetic Resonance Imaging; DRUG: Osimertinib. Primary outcome measures: Progression Free Survival (PFS) , From start of treatment to time of progression (in CNS or non-CNS disease) or death, whichever occurs first, assessed up to 63.7 months. Brief summary: This phase II trial studies how well osimertinib with or without bevacizumab works in treating patients with EGFR positive non-small cell lung cancer that has spread to the brain (brain metastases). Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab may stop or slow non-small cell lung cancer by blocking the growth of new blood vessels necessary for tumor growth. Giving osimertinib with or without bevacizumab may work better in treating patients with non-small cell lung cancer.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.